[HTML][HTML] CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
JR Palmeri, BM Lax, JM Peters, L Duhamel… - Nature …, 2024 - ideas.repec.org
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
JR Palmeri, BM Lax, JM Peters… - Nature …, 2024 - pubmed.ncbi.nlm.nih.gov
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs.
JR Palmeri, BM Lax, JM Peters, L Duhamel… - Nature …, 2024 - europepmc.org
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
JR Palmeri, BM Lax, JM Peters… - Nature …, 2024 - ui.adsabs.harvard.edu
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
[HTML][HTML] CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
JR Palmeri, BM Lax, JM Peters, L Duhamel… - Nature …, 2024 - ncbi.nlm.nih.gov
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
JR Palmeri, BM Lax, JM Peters… - Nature …, 2024 - econpapers.repec.org
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs.
JR Palmeri, BM Lax, JM Peters, L Duhamel… - Nature …, 2024 - europepmc.org
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …
antitumor immune responses in preclinical studies, clinical success has been limited by on …